Protagenic Therapeutics Completes Enrollment in Single Dose Portion of Phase 1 of Innovative Stress Disorder Trial
NEW YORK, NY / ACCESSWIRE / May 1, 2024 / Protagenic Therapeutics, Inc. (NASDAQ:PTIX), a leader in biopharmaceutical innovation, today announced the completion of enrollment in the single dose portion
12 Health Care Stocks Moving In Friday's Pre-Market Session
GainersTevogen Bio Holdings (NASDAQ:TVGN) shares rose 75.3% to $1.49 during Friday's pre-market session. The company's market cap stands at $245.2 million. Cryo-Cell International (AMEX:CCEL) shares i
12 Health Care Stocks Moving In Thursday's Intraday Session
GainersAclarion (NASDAQ:ACON) shares moved upwards by 66.7% to $0.48 during Thursday's regular session. The market value of their outstanding shares is at $3.4 million. Processa Pharma (NASDAQ:PCSA) s
KOPN, BTCM and CETX Among Mid-day Movers
Protagenic Therapeutics' Peptide PT00114 To Be Highlighted At Boston Summit In Presentation Titled "Novel Blood-Brain Barrier Penetrating Peptide: Opening New Doors in Neuro-Psychiatric Treatment" On April 23, 2024
Topic: Novel Blood-Brain Barrier Penetrating Peptide: Opening New Doors in Neuro-Psychiatric Treatment
Earnings Call Summary | Protagenic Therapeutics(PTIX.US) Q4 2023 Earnings Conference
The following is a summary of the Protagenic Therapeutics, Inc. (PTIX) Q4 2023 Earnings Call Transcript:Financial Performance:Protagenic Therapeutics reported an increase in Research and Development (
Protagenic Therapeutics FY23 EPS $(1.15) Down From $(0.82) YoY
Protagenic Therapeutics FY23 EPS $(1.15) Down From $(0.82) YoY
Protagenic Therapeutics Reports Fourth Quarter and Full Year 2023 Results
Transitioned from Pre-Clinical to Clinical Stage company in FY 2023Phase 1/2a trial, designed to assess both healthy volunteers and patients diagnosed with Treatment-Resistant Depression, PTSD or Gene
Earnings Scheduled For April 1, 2024
Companies Reporting Before The Bell • Mach Natural Resources (NYSE:MNR) is projected to report quarterly earnings at $0.92 per share on revenue of $213.43 million. • Sharps Technology (NASDAQ:STSS) is
Protagenic Therapeutics Successfully Concludes Third Cohort in Single Dose Portion of Phase 1 Trial for Stress-Related Neuropsychiatric Disorders
Next clinical progress update expected in April 2024NEW YORK, NY / ACCESSWIRE / March 27, 2024 / Protagenic Therapeutics, Inc. (NASDAQ:PTIX), a leader in biopharmaceutical innovation, advances its mis
Protagenic Therapeutics Announces Resolution of Nasdaq Deficiency Notice
NEW YORK, NY / ACCESSWIRE / March 21, 2024 / Protagenic Therapeutics, Inc. , a biopharmaceutical innovator, regained compliance with Nasdaq Listing Rule 5550 as the closing bid price of shares of PTIX
EYEN, BYSI and FENG Among Mid-day Movers
Protagenic Advances in Stress Disorder Treatment Trial
Protagenic Therapeutics Completes First Dose Escalation Step In Phase I Safety Clinical Trial For PT00114
Protagenic Therapeutics Completes First Dose Escalation Step In Phase I Safety Clinical Trial For PT00114
Protagenic Therapeutics Achieves First Clinical Safety Milestone With Its Novel Neuropeptide for the Potential Treatment of Stress-Related Disorders
Company Anticipates Reporting Complete Phase I Single Dose Results in AprilNEW YORK, NY / ACCESSWIRE / February 13, 2024 / Protagenic Therapeutics, Inc. , a biopharmaceutical innovator, announced a step
Wall Street Set to Open Slightly Higher Tuesday; Annual Inflation Declines to 3.1%
US stocks look set to open flat to slightly higher in Tuesday's trading session as investors parse inflation data that came out earlier in the morning and look to the start of the Federal Reserve's tw
Protagonist Reports 2-Year Follow Up Data From Rusfertide REVIVE Study at the ASH Annual Meeting
Protagonist Therapeutics, Inc. ("Protagonist" or the "Company") announced details from five abstracts at the American Society of Hematology 2023 Annual Meeting, including an oral presentation with two
Protagenic Therapeutics(PTIX.US) Officer Buys US$6,480 in Common Stocks
$Protagenic Therapeutics(PTIX.US)$ Officer Arrow Alexander K. purchased 8,000 shares of Common Stocks on Oct 12, 2023 at an average price of $0.81 for a total value of $6,480.Source: Announcement What
Protagenic Therapeutics Announces Date of Annual Shareholder Meeting
NEW YORK, NY / ACCESSWIRE / October 13, 2023 / Protagenic Therapeutics, Inc. (NASDAQ:PTIX) a biopharmaceutical company focused on developing therapies to treat stress-related neurologic disorders, tod
12 Health Care Stocks Moving In Tuesday's Intraday Session
GainersInovio Pharmaceuticals (NASDAQ:INO) shares moved upwards by 33.2% to $0.48 during Tuesday's regular session. The current volume of 13.0 million shares is 535.8% of Inovio Pharmaceuticals's aver
No Data